Usefulness of sparfloxacin against Chlamydia pneumoniae infection in patients with bronchial asthma

被引：3

作者：

Horiguchi, T ^{[1
]}

Miyazaki, J ^{[1
]}

Ohira, D ^{[1
]}

Watanabe, Y ^{[1
]}

Hayashi, N ^{[1
]}

Kobayashi, K ^{[1
]}

Torigoe, T ^{[1
]}

Fukumoto, K ^{[1
]}

Ito, T ^{[1
]}

Hirose, M ^{[1
]}

Sasaki, Y ^{[1
]}

Shiga, M ^{[1
]}

Kondo, R ^{[1
]}

Handa, M ^{[1
]}

Tachikawa, S ^{[1
]}

机构：

[1] Fujita Hlth Univ, Dept Resp Internal Med, Training Hosp 2, Nakagawa Ku, Nagoya, Aichi 4548509, Japan

来源：

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2005年 / 33卷 / 06期

关键词：

sparfloxacin; quinolone antibacterial agent; bronchial asthma; antibody titres; asthma symptoms;

D O I：

10.1177/147323000503300609

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The efficacy of sparfloxacin (SPFX) for the control of bronchial asthma was evaluated in 26 patients with suspected Chlamydia pneumoniae infection. Patients were randomly allocated to receive SPFX 200 mg/day (n = 14) or control treatment (n = 12) for 21 days. Significant improvements in serum C-reactive protein levels, and significant decreases in peripheral eosinophil counts, serum eosinophil cationic protein (ECP) and sputum ECP were observed in the SPFX-treated group at day 21. SPFX-treated patients also had a significantly reduced frequency of asthma symptoms, reduced inhalant Beta(2)-stimulant use, and significant increases in morning peak expiratory flow. At the end of the study, C. pneumoniae was undetectable in two SPFX-treated patients who underwent polymerase chain reaction testing, but one control patient who was tested still had detectable levels of C. pneumoniae. These results suggest that SPFX could be used to control bronchial asthma in patients with suspected persistent C. pneumoniae infection.

引用

页码：668 / 676

页数：9

共 50 条

[1] Chronic Chlamydia pneumoniae infection and bronchial asthma: Is there a link
Agarwal, A.
Chander, Y.
INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2008, 26 (04) : 338 - 341
[2] Chlamydia pneumoniae and bronchial asthma
Allegra, L
Blasi, F
ASTHMA - A LINK BETWEEN ENVIRONMENT, IMMUNOLOGY, AND THE AIRWAYS, 1999, : 186 - 189
[3] Relationship between Chlamydia pneumoniae infection and occurrence of bronchial asthma
施毅
郑闻
夏锡荣
张希龙
童茂荣
冯根宝
赵蓓蕾
胡兰萍
Journal of Medical Colleges of PLA, 2002, (02) : 129 - 133
[4] Chlamydia pneumoniae infection and asthma
Dokic, D.
Karkinski, D.
Aziri, S.
ALLERGY, 2012, 67 : 463 - 463
[5] Chlamydia pneumoniae infection and asthma
Dokic, D.
Karkinski, D.
Aziri, S.
ALLERGY, 2010, 65 : 541 - 541
[6] TREATMENT OF CHLAMYDIA PNEUMONIAE INFECTION IN PATIENTS WITH ASTHMA.
Dokic, D.
Aziri, S.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A34 - A34
[7] CHLAMYDIA-PNEUMONIAE INFECTION AND ASTHMA
HAHN, DL
LANCET, 1992, 339 (8802): : 1173 - 1174
[8] Chlamydia pneumoniae infection and inflammation in adults with asthma
Sävykoski, T
Harju, T
Paldanius, M
Kuitunen, H
Bloigu, A
Wahlström, E
Rytilä, P
Kinnula, V
Saikku, P
Leinonen, M
RESPIRATION, 2004, 71 (02) : 120 - 125
[9] Significance of antibacterial therapy of Chlamydophila pneumoniae infection in patients with bronchial asthma
Khamitov, RF
Palmova, LY
Novozhenov, VG
TERAPEVTICHESKII ARKHIV, 2004, 76 (10) : 91 - 94
[10] The joint effect of Chlamydia pneumoniae infection and mannose binding lectin mutation on development of bronchial asthma in childhood
Nagy, A
Kozma, GT
Keszei, M
Treszl, A
Budai, I
Falus, A
Szalai, C
TISSUE ANTIGENS, 2004, 64 (04): : 376 - 376

← 1 2 3 4 5 →